Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without disclosing safety and risk information.

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on ...

A recent photo of Ajith Kumar has gone viral on social media leaving fans shocked. The reason? Ajith looks like he has lost ...

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!